vi
LABORATORY PRODUCTS
New Compact Low Maintenance Hydrogen Generator
Quick and easy gas generation is now available at Quantitech with the new LNI Schmidlin range of Gas Generators.
The H2-FID hydrogen generator is ideal for operation with flame ionization detectors (FID), providing a source of pure hydrogen fuel gas at up to 10.5 Bar that compares well with cylinder gas.
The small contained volume (less than 40ml) also makes the H2-FID safe for operation in spaces where hydrogen cylinders are restricted and an automatic shut down procedure places the unit on standby in the event of any internal error.
The latest solid Polymer Electrolyte Membrane (PEM) technology available means that users of the H2-FID only require pure water (distilled/deionised) for trouble free long-term operation.
Dominic Duggan, Quantitech’s Sales Director, said: “Infrequent, inexpensive service requirements make the H2-FID a perfect choice for emission monitoring companies, especially where shipping or site use of cylinders is a problem. The LNI gas generator range will also prove popular with laboratories, for example to provide carrier gas for gas chromatography (GC) instruments.
“We believe that the elimination of cylinder shipping, handling and refilling combined with no flammable, high pressurised gas storage will also appeal to our customers.”
Circle no. 509 LAB PRODUCTS Circle no. 510
Diagnosis of Acute Myocardial Infarction Doctors in a specialist cardiology clinic in Heidelberg, Germany, have shown that the Elecsys®
Troponin T (cTnT) offers excellent precision (<10% CV) at the 99th
Troponin T
high sensitive (hs) assay from Roche helps to identify more patients with acute myocardial infarction (AMI) earlier, compared to less sensitive 4th
generation cardiac troponin assays. This high sensitive assay for cardiac percentile reference limit of a healthy
population, making it the first commercially available Troponin T assay to meet the recent ESC/ACCF/AHA/WHF recommendations for the diagnosis of myocardial infarction (MI).
“The improved performance of the high sensitive assay means that not only can we identify MI at an earlier opportunity, but we can also now identify more patients with MI (amongst those with symptoms of acute coronary syndrome (ACS)) than we could with the less sensitive assay,” commented Dr Evangelos Giannitsis from the Cardiology Clinic at the University Hospital, Heidelberg.
The ESC/ACCF/AHA/WHF redefinition of MI requires an increase or decrease of cardiac troponin to be demonstrated in patients with symptoms of ACS, with at least one of the concentrations greater than the 99th percentile of the reference population. Dr Giannitsis and his team found that, when used in this way, the Elecsys Troponin T hs assay increased the number of non- ST segment myocardial infarction (NSTEMI) diagnoses and enabled earlier detection of evolving NSTEMI3.
“The test has 100% tissue specificity and so it is excellent for the identification of patients with sub-clinical disease manifestations, which may also have an elevated cTnT. Interpretation of the high sensitive result should therefore consider the clinical presentation and the kinetics of the cTnT elevation. This is very helpful for distinguishing between chronic and acute disease. If there is a very rapid elevation or decline in cTnT between two measurements then this implies an acute condition such as AMI. If there is a more stable elevation, then it is more likely to be a chronic condition.”
The cardiology clinic in Heidelberg now uses the Elecsys Troponin T hs assay routinely to test patients presenting with ACS. The new Elecsys Troponin T hs assay is suitable for use on all cobas®
and Modular Analytics serum work areas. LAB PRODUCTS Circle no. 511
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204 |
Page 205 |
Page 206 |
Page 207 |
Page 208 |
Page 209 |
Page 210 |
Page 211 |
Page 212 |
Page 213 |
Page 214 |
Page 215 |
Page 216 |
Page 217 |
Page 218 |
Page 219 |
Page 220
